Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name of entity			

BioDiem Limited

**ABN** 

20 096 845 993

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>1</sup> +Class of +securities issued or to be issued

Ordinary fully paid shares and Options

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- i. 40,000,000 Ordinary Shares and 24,638,574 Listed Options
- ii. 10,380 Ordinary Shares
- Principal of the terms 3 +securities (eg, if options, exercise price and expiry date; if \*securities, partly paid the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- i. Ordinary shares and options (Options exercisable at \$0.08 (8 cents) per option on or before 31 December 2014)
- ii. Ordinary shares

01/08/2012 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Ordinary shares will rank equally

Upon any conversion of the options, the resulting ordinary shares will rank equally

- 5 Issue price or consideration
- i. \$0.05 (5 cents) per ordinary share plus freeattaching option
- ii. \$0.18 (18 cents)
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- i. Under renounceable rights issue
  - To provide on-going support for the LAIV programmes;
  - Continued development of BDM-I towards use in infectious disease applications, where new treatments are needed;
  - Finalise BDM-E data package for out licence;
  - Development of LAIV Vector technology towards proof of concept;
  - Further development of hepatitis D&B vaccine.
- ii. Rectification to take-up of May 2010 rights issue by Non-Executive Director
- 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in* relation to the +securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution N/A under rule 7.1A was passed

No

N/A

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

		<u> </u>		
6c	Number of *securities issued without security holder approval under rule 7.1	N/A		
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A		
6f	Number of securities issued under an exception in rule 7.2	N/A		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	i. 5 December 2012 ii. 14 September 2012		
		37 1		
		Number	+Class	
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	142,105,934 24,638,574	Ordinary Shares Fully Paid Listed Options	
9		Number	<sup>+</sup> Class	
	Number and +class of all +securities	80,000	Unlisted ESOP options,	
	not quoted on ASX (including the securities in section 2 if applicable)	160,000	exercise price \$0.14, expiry 04- Jul-13 Unlisted ESOP options, exercise price \$0.136, expiry 23- Jul-14	

o1/08/2012 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Renounceable
13	Ratio in which the *securities	1 share for every 2 shares held
	will be offered	1 option for every 2 new shares issued
		1 option for every 2 shares underwritten or
		placed by the underwriter
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Shares and options
15	<sup>+</sup> Record date to determine	11 October 2012
	entitlements	
		-
16	Will holdings on different	Yes
	registers (or subregisters) be aggregated for calculating	
	entitlements?	
17	Policy for deciding entitlements	Rounded up
,	in relation to fractions	nounueu up
18	Names of countries in which the	United States of America
	entity has *security holders who	United Kingdom
	will not be sent new issue documents	Ireland
		China
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
	•	
19	Closing date for receipt of	27 November 2012
	acceptances or renunciations	,
	•	
20	Names of any underwriters	Patersons Securities Limited
	,	
	,	
21	Amount of any underwriting fee	4% of shortfall (max \$18,554)
	or commission	+ up to 10,162,448 Underwriter options

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Names of any brokers to the **Patersons Securities Limited** 22 issue Fee or commission payable to 2% Management fee 23 the broker to the issue Amount of any handling fee N/A 24 payable to brokers who lodge acceptances or renunciations on behalf of \*security holders If the issue is contingent on N/A 25 \*security holders' approval, the date of the meeting 26 Date entitlement and acceptance 8 November 2012 form and prospectus or Product Disclosure Statement will be sent to persons entitled If the entity has issued options, N/A 27 and the terms entitle option participate holders to exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if 2 October 2012 applicable) Date rights trading will end (if 20 November 2012 29 applicable) How do +security holders sell Security holders should instruct their 30 their entitlements in full through stockbroker personally and provide the a broker? details as requested on the entitlement and acceptance form accompanying the prospectus. Do not forward requests for sale to the Share Registry. Security holders should instruct their How do +security holders sell 31 of their entitlements stockbroker personally and forward the slip through a broker and accept for on the entitlement and acceptance form the balance? accompanying the prospectus with the Subscription Monies or make payment using BPAY® for the quantity they wish to accept.

01/08/2012 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

How do \*security holders dispose of their entitlements (except by sale through a broker)?

A Standard Renunciation Form must be used for an off market transfer of Entitlements. These forms may be obtained through the security holder's Stockbroker or the Share Registry. The completed Standard Renunciation Formmust be forwarded to the Registry by the transferee with the relevant payment and must be received by the close of the Offer.

<sup>+</sup>Despatch date

5 December 2012

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of securities (*tick one*)
- (a) Securities described in Part 1
- (b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

A copy of any trust deed for the additional +securities

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)					
38	Number of securities for which <sup>+</sup> quotation is sought	N/A			
39	Class of *securities for which quotation is sought	N/A			
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A			
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)	N/A			
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class		

o1/08/2012 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 5 December 2012..... (Company secretary)

Print name: ......Melanie Leydin.....

== == == ==

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.